Multiple Sclerosis Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Multiple Sclerosis stocks.

Multiple Sclerosis Stocks Recent News

Date Stock Title
Nov 19 TEVA Teva Pharmaceutical Industries Limited (TEVA) Jefferies London Healthcare Conference (Transcript)
Nov 18 SNY FDA Accepts SNY and REGN's Dupixent Re-Submitted sBLA for Urticaria
Nov 16 TEVA Plant-Based API Market Poised To Hit $52 Billion By 2034, Driven By Psychedelics And Cannabinoids
Nov 15 SNY How analysts are reacting to RFK Jr. as Trump's HHS pick
Nov 15 SNY FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
Nov 15 SNY Analysts think Wall Street's reaction to the RFK Jr. news is 'overdone.' Sort of.
Nov 15 SNY Stocks to Watch Friday: Applied Materials, Alibaba, Domino's, Novo Nordisk
Nov 15 SNY Trump’s RFK Jr. Pick Weighs on Vaccine Makers
Nov 15 SNY Regeneron, Sanofi say resubmitted application to expand Dupixent label accepted in U.S.
Nov 15 IMUX Insider Buys Additional US$100k In Immunic Stock
Nov 15 SNY European Vaccine Makers Under Pressure After Trump Picks RFK Jr to Lead Health Department
Nov 15 CGEN Compugen Ltd. (NASDAQ:CGEN) Stock's Been Sliding But Fundamentals Look Decent: Will The Market Correct The Share Price In The Future?
Nov 15 SNY EMA’s CHMP recommends Sanofi’s Sarclisa approval for multiple myeloma
Nov 15 SNY Drugmaker stocks slide as Trump picks vaccine sceptic RFK Jr for US health job
Nov 15 SNY Press Release: Dupixent sBLA accepted for FDA review for the treatment of chronic spontaneous urticaria
Nov 15 SNY Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Nov 15 SNY Viking Fund Management Sells Big Oil Stocks In Q3, Cuts Tesla Position In Half, Adds To Largest Position Broadcom
Nov 14 SNY Vaccine makers close lower amid reports RFK Jr may head HHS (update)
Nov 14 TEVA Druckenmiller's Duquesne closes some media holdings, loads into regional banks, among Q3 trades
Nov 14 SNY Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Multiple Sclerosis

Multiple sclerosis (MS) is a demyelinating disease in which the insulating covers of nerve cells in the brain and spinal cord are damaged. This damage disrupts the ability of parts of the nervous system to communicate, resulting in a range of signs and symptoms, including physical, mental, and sometimes psychiatric problems. Specific symptoms can include double vision, blindness in one eye, muscle weakness, trouble with sensation, or trouble with coordination. MS takes several forms, with new symptoms either occurring in isolated attacks (relapsing forms) or building up over time (progressive forms). Between attacks, symptoms may disappear completely; however, permanent neurological problems often remain, especially as the disease advances.While the cause is not clear, the underlying mechanism is thought to be either destruction by the immune system or failure of the myelin-producing cells. Proposed causes for this include genetics and environmental factors such as being triggered by a viral infection. MS is usually diagnosed based on the presenting signs and symptoms and the results of supporting medical tests.There is no known cure for multiple sclerosis. Treatments attempt to improve function after an attack and prevent new attacks. Medications used to treat MS, while modestly effective, can have side effects and be poorly tolerated. Physical therapy can help with people's ability to function. Many people pursue alternative treatments, despite a lack of evidence of benefit. The long-term outcome is difficult to predict, with good outcomes more often seen in women, those who develop the disease early in life, those with a relapsing course, and those who initially experienced few attacks. Life expectancy is on average 5 to 10 years lower than that of an unaffected population.Multiple sclerosis is the most common immune-mediated disorder affecting the central nervous system. In 2015, about 2.3 million people were affected globally with rates varying widely in different regions and among different populations. That year about 18,900 people died from MS, up from 12,000 in 1990. The disease usually begins between the ages of 20 and 50 and is twice as common in women as in men. MS was first described in 1868 by Jean-Martin Charcot. The name multiple sclerosis refers to the numerous scars (sclerae—better known as plaques or lesions) that develop on the white matter of the brain and spinal cord. A number of new treatments and diagnostic methods are under development.

Browse All Tags